MR Lymphography and Magnetic Sentinel Lymph Node Biopsy in Melanoma Patients
NCT05569707 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2022-10-06
Summary
The sentinel lymph nodes (SLNs) are the first lymph nodes (LNs) to drain the tumor site and therefore the first LNs to bare metastases. Hence the importance to investigate these LNs for the best treatment strategy. Current-standard-of-care for melanoma patients with a melanoma stage of pT1b or higher, involve a surgical procedure, referred to as SLN biopsy (SLNB). The SLNB procedure involves a combined detection procedure using a radio-active tracer and blue dye followed by surgical dissection and evaluation of the LNs at the histopathology department. Due to the use of radioisotopes, this procedure suffers from several disadvantages such as limited availability, strict rules and regulations, degradation time in patient and radioactive load for user and patient.
To overcome the limitations of a radioactive tracer, a magnetic SLNB was developed which is facilitated by super paramagnetic iron-oxide (SPIO) nanoparticles. This potentially offers numerous benefits making surgery planning more flexible: no exposure to radiation, easy accessibility of the tracer, long shelf life and long half time in the patient. However, the currently available magnetometer for intraoperative detection of SPIO-enhanced LNs is hampered by a relatively low detection depth, biological noise, and effects of surgical equipment. Therefore, surgeons need to switch to plastic or carbon equipment and the system needs to be balanced prior to each measurement, which increases the surgery time.
A new and effective way to localize SPIOs is differential magnetometry (DiffMag). This patented detection principle, developed by MD\&I group at University of Twente (UT), utilizes the nonlinear magnetic response of nanoparticles. An additional advantage of SPIOs is their visibility on MRI, which could provide mapping the SLNs preoperatively. Especially in patients with melanomas on the abdomen or back this would be very useful to see which lymph node stations are connected to the melanoma. In addition, studies have shown that SPIOs are absorbed into lymph nodes in different ways, depending on the presence of metastases. SPIO-enhanced MR lymphography could therefore provide an opportunity for a non-invasive preoperative assessment of nodal status.
In this pilot study the investigators want to evaluate the clinical use of the DiffMag handheld probe. Moreover, the investigators want to map the lymph nodes (metastases) preoperatively using MR lymphography.
Conditions
- Melanoma (Skin)
Interventions
- DEVICE
-
Magnetic sentinel lymph node biopsy by use of Magtrace®, in combination with SentiMag® and DiffMag
In addition to the standard procedure, SLNs will be detected using two types of magnetometers (SentiMag® \& DiffMag) in combination with SPIO particles (Magtrace®).
Sponsors & Collaborators
-
University of Twente
lead OTHER
Principal Investigators
-
Lejla Alic, PhD · University of Twente
-
Anneriet Dassen, PhD · Medisch Spectrum Twente Enschede
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-31
- Primary Completion
- 2024-01-31
- Completion
- 2024-03-31
Countries
- Netherlands
Study Locations
More Related Trials
-
Clinical Study of 18F -FAPI-RGD in Renal Tumor
NCT05976607 ·Status: COMPLETED
-
Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI
NCT03132090 ·Status: UNKNOWN ·Phase: NA
-
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
NCT01410630 ·Status: COMPLETED
-
The Value of Preoperative Sentinel Lymph Node Mapping by Pelvic MR Lymphangiography and SPECT-CT in Cervical Cancer
NCT01777230 ·Status: WITHDRAWN
-
Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5
NCT00743353 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Clinical Study of 18F-FAPI-RGD in Breast Tumors
NCT05976620 ·Status: COMPLETED
-
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy
NCT01666353 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Fluorescence Imaging in Head and Neck Cancer
NCT03297957 ·Status: TERMINATED ·Phase: NA
-
MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma
NCT05626127 ·Status: UNKNOWN
-
[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis
NCT02700763 ·Status: TERMINATED ·Phase: NA
-
Sentinel Lymph Node Mapping In Endometrial Cancer
NCT03778255 ·Status: UNKNOWN ·Phase: NA
-
Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
NCT01573494 ·Status: COMPLETED ·Phase: NA
-
Pembrolizumab-PET Imaging
NCT02760225 ·Status: COMPLETED ·Phase: NA
-
A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma
NCT00912730 ·Status: COMPLETED
-
Mapping of Sentinel Lymph Node Drainage Using SPECT (SUSPECT) (SUSPECT)
NCT02572661 ·Status: COMPLETED ·Phase: NA
-
18F-FLT PET Imaging in Patients With Advanced Melanoma
NCT02891616 ·Status: TERMINATED ·Phase: PHASE1
-
Study of the Angiogenesis by PET/CT in Patients With Lymphoma
NCT02490891 ·Status: COMPLETED ·Phase: PHASE2
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
NCT01806675 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy
NCT02969278 ·Status: UNKNOWN ·Phase: NA
-
MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma
NCT02733887 ·Status: UNKNOWN ·Phase: NA
-
7T MRI Scan for the Early Detection of Melanoma Brain Metastases
NCT04941430 ·Status: TERMINATED ·Phase: NA
-
PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study
NCT01266096 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
NCT05259709 ·Status: RECRUITING ·Phase: PHASE1
-
Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer
NCT05446324 ·Status: RECRUITING ·Phase: PHASE3
-
Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans
NCT02970786 ·Status: UNKNOWN ·Phase: PHASE1